Marshall Wace, LLP Arcturus Therapeutics Holdings Inc. Transaction History

Marshall Wace, LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$24.35 - $44.39 $950,818 - $1.73 Million	-39,048 Reduced 46.34%	45,219 $1.1 Million
Q1 2024 May 15, 2024	BUY	$31.23 - $42.99 $2.63 Million - $3.62 Million	84,267 New	84,267 $2.85 Million
Q3 2023 Nov 14, 2023	BUY	$25.44 - $37.35 $143,456 - $210,616	5,639 Added 6.68%	90,010 $2.3 Million
Q2 2023 Aug 14, 2023	BUY	$23.94 - $32.36 $2.02 Million - $2.73 Million	84,371 New	84,371 $2.42 Million
Q4 2021 Feb 14, 2022	SELL	$34.2 - $47.56 $378,320 - $526,108	-11,062 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$27.88 - $58.25 $308,408 - $644,361	11,062 New	11,062 $528,000
Q4 2020 Feb 16, 2021	SELL	$34.61 - $123.66 $266,116 - $950,821	-7,689 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$37.49 - $63.19 $288,260 - $485,867	7,689 New	7,689 $330,000

180

25.7M

195K

133K

Ticker ARCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,576,400
Market Cap $426M
Description
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.